

October 27-28, San Francisco, USA

**Conference Brochure** 

# Pioneering The Future Of Biomarkers & Precision Medicine



**10**Content Tracks
Across Two Days



10+
Hours of prearranged 1:1
Meetings



**30+** Partners



**1,000+** Attendees

Composed of 3 Groundbreaking Programmes!




**Biomarkers** 



Spatial Biology for Precision Medicine



Digital Pathology & Al



Over 130 Industry-Leading Speakers Including...



\* KEYNOTE SPEAKER

**LEROY HOOD,**Co-Founder, Institute of Systems Biology

**Don't Miss His Keynote at 08.40 on Day 1:** The Synergy Of Data-Driven Health And Data-Driven Peptide Drug Discovery



IDA SII

Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley); Co-Director, UCSF UC Berkeley Joint Program in Computational Precision Health

Ida Will Open Day 2 of The Meeting At 9.00 With A Talk On Harnessing Computational Tools In Precision Medicine: Implementation & Future Directions



### 🚔 PANEL DISCUSSION

#### **IVDR REGULATIONS & THEIR IMPACT**

Join Us For The Interactive Panel Discussion On Day 1 At 11.55 With The Panellists Below:

**Janet Jin**, Executive Director, Clinical Imaging and Diagnostics Clinical Biomarker and Diagnostics, Amgen

**Hongda Zhao**, Director of Precision Medicine and Digital Health in Global Regulatory Sciences, BMS

#### AI-POWERED PRECISION MEDICINE

Keep Up To Date With The Latest AI Applications With This Special Panel On Day 2 At 12.35

**IDA SIM,** Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley), UCSF Chief Research Informatics Officer, Co-Director, UCSF UC Berkeley Joint Program in Computational Precision Health

MIKE MONTALTO, Vice President, Precision Medicine, Global Development, Amgen MANOJ KANDPAL, Director of Research Bioinformatics, Rockefeller University



#### **WELCOME TO**

## Biomarkers & Precision Medicine US 2025

Welcome to Biomarkers & Precision Medicine US 2025, Oxford Global's flagship US event bringing together the leading innovators in Precision Medicine at the Westin St. Francis San Francisco on Union Square, October 27-28.

Join us for two immersive days of expertly created content addressing the most pressing challenges, spotlighting breakthrough innovation, and uncovering emerging technologies across three cutting-edge programmes: Biomarkers 2025, Spatial Biology for Precision Medicine, and Digital Pathology & Al.

Engage in high-level discussions and expertly tailored sessions that showcase the latest advancements in biomarker driven research, spatial multi-omic analysis, and digital pathology. Our carefully crafted agenda highlights pioneering developments driving the future of diagnostics and therapeutic innovation. Hear cutting edge insight from leading experts as they explore the integration of spatial and multi-omic insights into biomarker development, the role of Al in transforming pathology workflows, and evolving strategies for regulatory success around IVDR and latest developments in companion diagnostics. Sessions will also examine how these technologies are shaping clinical decision-making, enhancing patient stratification, and advancing precision-quided therapies.

In addition to groundbreaking scientific presentations and interactive discussions, this event offers invaluable opportunities to network with industry leaders, cutting-edge technology providers, emerging innovators and key investors. Explore our vibrant exhibition room, start-up zone and join exclusive plenary keynotes, panel discussions and fireside chats with renowned authorities taking place in track 1.

> Don't miss the chance to connect with key industry leaders and stay at the forefront of the next-generation advancements set to transform precision medicine.



Director of Production & Content -Precision Medicine Brand, Oxford Global









Sign up for our monthly newsletter to keep up with all things **Precision Medicine** 









Welcome

Highlights

Special Event **Features** 

**Sponsors** 

Agenda At A Glance

Speakers

PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue





#### WHAT'S NEW

## Benefits Of Attending



#### **Unified Vision for Precision Medicine**

The latest developments in Biomarkers, Spatial Biology, and Digital Pathology research come together under one roof to drive forward precision medicine. Together, these complimentary fields offer a comprehensive approach to advancing patient care and fostering collaboration across disciplines.



Stay ahead of evolving regulatory landscapes and navigate IVDR regulations with talks, panel discussions & roundtables focused on providing direction to this conundrum.



## Gain exclusive insights into cutting-edge biomarker research

Explore the latest in biomarker discovery, validation, and clinical implementation across oncology, neuroscience, immunology, rare diseases etc.



Gain exclusive insights into cutting-edge biomarker research - explore the latest in biomarker discovery, validation, and clinical implementation across oncology, neuroscience, immunology, rare diseases etc.



Unlock the potential of AI - discover how AI-powered biomarker analysis, spatial biology, and digital pathology are revolutionizing drug development, patient stratification & Image analysis.



## Interdisciplinary learning is key to driving Precision Medicine

Join dynamic plenary panel discussions bringing together experts across biomarkers, diagnostics, genomics, and AI to explore collaborative innovation and real-world application.



## Engage with thought leaders in translational research

Gain firsthand insights from leading scientists, clinicians, and regulatory experts on biomarker adoption, clinical trial design, and strategies for precision medicine implementation.



## Discover groundbreaking biomarker technologies shaping the future

Deep dive into mass spectrometry, flow cytometry, multiplex imaging, and single-cell sequencing techniques advancing biomarker analysis.



## Explore omics technologies & diagnostics driving research

Sessions will address cfDNA, ctDNA, CTCs, proteomics, metabolomics and transcriptomics.

## DON'T MISS THESE Interactive Panels

#### **BIOMARKERS**

Challenges In Translating Exploratory Biomarkers Into The Clinic

IVDR Regulations & Their impact

Application and Integration of AI/ML in Biomarker Science

Application & Integration Of Proteomic Biomarkers In Precision Medicine

Implementing Patient-Centric Biomarkers In Clinical Trials

#### PRECISION MEDICINE

Al-Powered Precision Medicine

Building The Next Era Of Precision Medicine: Stakeholder Collaboration Across Biomarkers, Diagnostics, Genomics & Therapeutic Innovation

#### DIGITAL PATHOLOGY

Building A Business Case For Digital Pathology

Real World Learning From Deploying Digital And Computational Pathology At Scale

Digital Pathology in Pharma – Overcoming Integration Strategies & Future Proofing

#### SPATIAL BIOLOGY —

Addressing The Future Needs Of Spatial Multi-Omics

Data Sharing And Reproducing Analyses In The World Of Spatial Transcriptomics

> Moving Towards Clinical Trial & Discovery Phases

Computational Methods To Assist In The Identification, Classification & Visualization Of Complex Multi Model Datasets



Welcome

Highlights

Special Event **Features** 

**Sponsors** 

Agenda At A Glance

Speakers

PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue





#### SPECIAL EVENT FEATURES

# **Big Attendance Meets Intimate Connections**

## Day 2 Breakfast Roundtables & Workshops

Mark your calendars for our exclusive crossprogramme roundtables on day two of the event. Join in from 8:15 - 9:00am to discuss key topic areas with one of our experts in a lively informal setting whilst you enjoy a coffee & a pastry before the day ahead.

## - Day One & Two -**Plenary Panel Discussions**

Don't miss our exclusive Plenary Panel Discussions taking place on the main stage. Join leading experts and industry innovators as they tackle the critical themes shaping the future of precision medicine. These dynamic, interactive sessions will explore the latest breakthroughs and challenges in biomarker development, Al integration, and personalized healthcare.

## Plenary Panel Discussion Session 1: **Building the Next Era of Precision Medicine**

Discover how cross-sector collaboration between biomarker developers, diagnostic innovators, genomic scientists, and therapeutic leaders is driving the next wave of precision medicine breakthroughs.

### Plenary Panel Discussion Session 2: **AI-Powered Precision Medicine:**

Gain insights into the transformative role of Al in personalizing patient care, and explore the real-world challenges of integrating Al into clinical workflows.

## Day One - Opening Keynote Address - Leroy Hood

Join Leroy Hood, Co-Founder of the Institute of Systems Biology and a pioneer in biotechnology, systems biology, and precision medicine, for a visionary keynote on the intersection of data-driven healthcare and peptide drug discovery. He will explore how integrated phenome and genome analysis can enable personalised wellness, healthy ageing, and disease prevention. Dr. Hood will also highlight breakthroughs in peptide therapeutics, where large-scale DNA synthesis and high-throughput screening are accelerating innovation. Explore how these two approaches can work together to reshape the future of precision medicine.



Highlights

Welcome

Special Event **Features** 

**Sponsors** 

Agenda At A Glance

Speakers

**FULL** PROGRAMME:

Day One 27 Oct, 2025


Day Two 28 Oct, 2025

Venue Information

**Book Now** 

## Day Two - Opening Keynote Address - Ida Sim

Join Ida Sim, Professor of Medicine at UCSF and Co-Director of the UCSF-UC Berkeley Joint Program in Computational Precision Health, for a forward-looking keynote on the role of computational tools in transforming precision medicine. She will explore how Al, data integration, and digital infrastructure are enabling scalable, personalised healthcare across clinical and research settings. Drawing on real-world examples, Dr. Sim will also address the future of the field, including predictive modelling, real-time analytics, and the ethical, regulatory, and equity challenges of data-driven care



**Computational** PRECISION HEALTH

## Site Tour - UCSF Clinical Digital Lab

Join us for an exclusive behind-the-scenes tour of UCSF's cutting-edge Digital Pathology facilities on October 29th. This 40-minute experience includes:

- Guided department walk-through
- Live digital workflow demonstration
- Technical Q&A with IT experts
- User experience Q&A with UCSF pathologists

Two tour slots are available at **09:00** and **10:30**. Each tour is limited to 10 participants, so places can be reserved during event registration.







## WHY PARTNER WITH **OXFORD GLOBAL?**

At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

## ✓ Arrange 1-1 Meetings

Benefit from quaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

## Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

#### Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

## Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

## Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

## ✓ Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.

LEARN MORE

DRIVE INNOVATION & ACCELERATE RESEARCH

## Who Is Partnering?

**Platinum Sponsor** 



**Gold Sponsors** 



**Olink** 



PRECISION



SINGULAR









Silver Sponsors























vizgen

**Bronze Sponsors** 











RARECYTE

proteome



**Network & Programme Sponsors** 

Ardigen

nomic



PIXELGEN



**PROSCIA** 





an IQVIA business

RULES BASED MEDICINE



SAPIENT











Venue







Welcome

Highlights

Special Event **Features** 

**Sponsors** 

Agenda At A Glance

FULL

PROGRAMME:

Day One

27 Oct, 2025





Join world-leading experts in biomarker research and development for this in-person meeting in the heart of San

Francisco. Discover groundbreaking insight into biomarker science, patient stratification, companion diagnostics, regulatory considerations, clinical development and trial design and explore cutting-edge innovations driving precision medicine forward.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Biomarkers
- Biomarker Discovery
- Biomarker Identification
- Biomarker Validation
- Clinical Biomarkers
- Pre-Clinical
- Translational Science

- Clinical Development
- Precision Medicine
- Early Detection
- Enabling Technologies
- Multiplex Technologies
- Genomic Biomarkers
- Regulation

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Biomarker **Technologies**
- · Diagnostic Biomarkers

- Imaging Techniques
- Biomarker Analysis
- Proteomics
- Metabolomics

- Clinical
- Development
- Multiplex tools
- Digital Pathology

#### Day One

#### **Track 1: Biomarkers for Diagnostics & Clinical Development**

- Biomarker technologies for diagnostics development
- Multiplexing, Flow cytometry, Al/ ML for biomarker data analysis
- Multi-omics approaches to diagnostics & precision medicine
- Developing nextgen diagnostic methods & approaches
- Diagnostic-driven therapies
- Towards the clinic with optimised market access & patient adoption
- Transforming clinical development through biomarker driven clinical trial design and data analysis
- Precision medicine case studies for neuroscience, immunology, respiratory etc
- IVDR Regulations and their impact
- Companion diagnostic development
- · Liquid biopsy biomarkers for disease monitoring, multi-cancer screening & early detection /ultrasensitivity/ MRD

## Track 2: Identification, Qualification & Validation of Biomarkers in Translational

- Biomarker discovery tools and technologies
- Biomarker strategies for patient identification
- Biomarkers to detect, predict / monitor response to treatment
- Imaging, digital and liquid biomarkers
- Scientific & regulatory considerations for the qualification analysis & validation of biomarkers
- · Technologies and approaches to improve target engagement, early diagnostic biomarkers and how best to incorporate biomarkers into drug development, safety, patient stratification and clinical trials

#### **Day Two**

#### **Track 1: Technologies for Biomarker Analysis**

- · Technology approaches, techniques & analysis flow cytometry, mass spectrometry, proteomics, metabolomics
- Using digital biomarker to inform clinical decisions
- Biomarker assay optimization & validation
- · AI/ML biomarker methods & data tools for biomarker discovery, diagnostics, prognostics, patient stratification & precision medicine

#### Track 2: Biomarker & Multi-Omic Approaches in Discovery & Clinical Development for Personalized Treatment

- Precision medicine approaches for personalized therapies
- · Precision oncology and molecular profiling
- · Single plex & multiplex technologies
- Biofluid-based molecular biomarkers: cfDNA, ctDNA and CTCs
- · Validating & verifying genomic markers in preclinical drug development
- · Multi-omic and multimodal data analysis
- Exploratory/clinical endpoint biomarkers needed to support clinical trials
- Patient centric biomarkers / profiling / biosignatures for clinical development strategy
- Implementing biomarkers in precision oncology
- Translating biomarker research from bench to bedside & back again



Welcome

Highlights

Special Event **Features** 

**Sponsors** 

Agenda At A Glance

Speakers

**FULL** PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information







### AGENDA AT A GLANCE

# Spatial Biology for Precision Medicine



Join leaders, experts, and researchers in our Spatial Biology for Precision Medicine programme, connecting global academic & research organisations as well as pharma representatives for high-level discussions on the latest innovations in spatial research & technologies.

Forward looking visionary leaders will discuss the current state of the industry, market trends and future growth areas aiding the application of spatial technologies in the clinic as well as the rise of digital pathology.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Spatial Transcriptomics
- Spatial Proteomics
- Systems Biology

- Molecular Medicine
- Spatial Genomics
- Spatial Metabolomics

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Spatial Imaging Platforms
- Spatial Data Analysis Tools
- Spatial Genomics

- Tissue Imaging & Prep
- Single Molecule Imaging
- Bioinformatics

#### Day One

#### Track 3: Spatial Multi Omics Tools, Techniques & Approaches

- Translating spatial imaging techniques & approaches into clinics
- Transcriptomics, proteomics, genomics & metabolomics breakthrough tools, techniques & approaches for precision medicine
- Single-cell transcriptome / RNA-seq
- Multi-modality processing
- Standardization of workflows

#### Track 4: Spatial Bioinformatics, Data Analytics & Interpretation

- Data access, interoperability & standardization
- Data integration, visualization, handling & insight
- Cell-cell interaction
- Algorithm design for spatial data
- Accelerating the discovery & characterization of biomarkers and drug targets using
- Overcoming challenges in multi-omic data acquisition & analysis
- · Computational methods to assist in the identification, classification and visualization of complex multi model datasets
- Impacting disease research informing assessment of treatment and action mechanisms / deciphering dynamics of cell interactions
- Adoption & utilization of AI & ML for spatial analyses in R&D

#### Day Two

#### Track 3: Applications of Spatial Research & Technologies in Biology

- Accelerating the discovery of novel biomarkers and drug targets using spatial imaging
- Case studies from the areas of:
- » Personalized / precision medicine
- » Oncology & Tumor microenvironment
- » Neuroscience
- » Cardiovascular, Immunological, Infectious diseases etc
- Part 2 Spatial Technologies for Clinical Development
- Diagnostics applications of spatial and multi-omics tissue analysis
- Translating spatial imaging techniques & approaches into clinics
- Supporting clinical trials & patient monitoring

#### Track 4: Image Analysis & Al Powered Imaging for Digital Pathology & Spatial Biology

- Examining the latest developments in imaging technologies & quality
- Image format standardization
- Intersection of digital pathology & spatial biology
- Tissue imaging & analysis
- Techniques and Al guided technology integration of Al into workflows
- Working with AI from a scientist's perspective
- Accelerating the discovery of novel biomarkers and drug targets
- Label free imaging technologies imaging mass spec



Welcome

Highlights

Special Event **Features** 

**Sponsors** 

Agenda At A Glance

Speakers

PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

> Venue Information









Gather with leading innovators in digital pathology for an inperson event in the heart of San Francisco.

Dive into the latest advancements in Al-driven image analysis & computational pathology, as well as hearing from the challenges faced and lessons learnt from those who have already implemented DP & Al into their workflow so that you can join others in shaping the future of pathology.

VPs, Directors & Senior Managers from leading pharma & biotech companies and research institutions in the following fields and more:

- Digital Pathology
- Computational Pathology
- Image analysis
- Biomedical Informatics & Al
- Computational Medicine
- Pathology IT

- Immunohistochemistry
- Histopathology
- · Toxicology and Safety Sciences
- NHS transformation
- Pathology
- Diagnostics

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1:1 meeting opportunities will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Digital Pathology Hardware
- Scanners
- Monitors
- Digital Pathology Software
- Image analysis
- Multi-modal image analysis

- Image Management
- Cloud computing/ storage
- End to End Solutions
- LIS
- Enterprise Imaging & Healthcare IT
- Al Algorithms

#### Day One

#### Track 5: Computational Pathology & Al

- Implementing AI based precision pathology
- Advancing machine and deep learning algorithms
- Improving WSI workflow efficiency
- Pathology PACS and informatics
- Cloud computing / storage solutions
- Computational Pathology in Precision Oncology
- Deep learning application for digital biomarker discovery
- Ground truth data and technology for biomarker assessment
- · Advances, challenges, benefits & future developments of Digital Pathology, and the implications for pathology practice

#### Day Two

## Track 5: Image Analysis & AI Powered Imaging for Digital Pathology & Spatial

- Examining the latest developments in imaging technologies & quality
- Image format standardization
- Intersection of digital pathology & spatial biology
- Tissue imaging & analysis
- Techniques and Al guided technology integration of Al into workflows
- Working with AI from a scientist's perspective
- Accelerating the discovery of novel biomarkers and drug targets
- Label free imaging technologies imaging mass spec
- Relevant spatial parameters in different model systems
- Spatial multiplexed imaging for disease characterization
- · Quality assurance, control & improvement



Welcome

Highlights

Special Event **Features** 

**Sponsors** 

Agenda At A Glance

Speakers

PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue







# **Confirmed Speakers**

**KEYNOTE SPEAKERS** 



LEROY HOOD, Co-Founder, Institute of Systems Biology



IDA SIM, **Professor of Medicine** (UCSF) and Computational Precision Health (UCSF and UC Berkeleu): Co-Director, UCSF **UC Berkeley Joint Program** in Computational Precision

**HEALTH** 



AMRITA PATI, Executive Director, Precision Medicine Associate Center Director, Computational Biology, Amgen



FLSA FLORES. Basic Science, Moffitt Cancer



ANIL SOOD, Professor & Vice Chair for Translational Research, Co-**Director of the Center** for RNA Interference and Non-Coding RNA **MD Anderson Cancer Center** 



MIKE MONTALTO, Vice President, Precision Medicine, Amgen



COREY ARNOLD, **Professor and Vice Chair** of Research, Radiology; Professor, Pathology, Bioengineering, and Electrical & Computer Engineering, UCLA

#### **ABHISHEK AGGARWAL**

Director, Pathobiology, Gilead Sciences

### **ABEER OBAID**

Senior Scientist, Abbvie

#### **ALEXANDER KLIMOWICZ**

Principal Scientist, Boehringer Ingelheim

#### **AMRITA PATI**

Executive Director, Precision Medicine Computational Biology, Amgen

#### **AMY L DELSON**

Laboratory Architecht, Research Advocate, I-SPY Breast Cancer Clinical Trial Mark

#### **ANIL SOOD**

Professor & Vice Chair for Translational Research, Co-Director of the Center for RNA Interference and Non-Coding RNA, MD Anderson Cancer Center

#### **BOBBIE-IO WEBB-ROBERTSON**

Division Director, Chief Scientist, Pacific Northwest National Laboratory

#### **COREY ARNOLD**

Professor and Vice Chair of Research, Radiology; Professor, Pathology, Bioengineering, and Electrical & Computer Engineering, UCLA

#### **DANIELLE TAN**

Senior Scientist I, BioMarin

#### **DAVID WEINGEIST**

Scientific Director, Oncology Precision Medicine & Diagnostics, Johnson & Iohnson Innovative Medicine

#### **DIANE STEPHENSON**

Vice President, Neurology; Executive Director, Critical Path for Parkinson's, Critical Path Institute

#### **ELSA FLORES**

Associate Center Director, Basic Science, Moffitt Cancer Center

#### **EVAN KELLER**

Professor & Director of Single Cell Spatial Analysis Program, University of Michigan

#### **EUGEAN JIWANMALL**

Senior Research Analyst for Medical Policy & Technology Assessment, Independence Blue Cross

#### **FANGYAO HU**

Senior Principal Scientist AI, Safety Assessment, Genentech

#### **GERALD OUON**

Associate Professor, Department of Molecular and Cellular Biology, University of California, Davis

#### **GUNEET WALIA**

Senior Director, Data Science & Digital Health, Johnson & Johnson Innovative Medicine

#### **HARSH THAKER**

Professor, Department of Pathology, Vice Chair, Digital and Integrative Pathology, Director, Anatomic Pathology, University of Texas Medical Branch - Galveston

#### **HOUSHENG HANSEN HE**

Professor, University of Toronto

#### I-MING WANG

Director, Translational Oncology, Pfizer

#### **IDA SIM**

Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley); Co-Director, UCSF UC Berkeley Joint Program in Computational Precision Health

#### **JACK CHEN**

Director, Translational Research Group Lead, Precision Medicine, AbbVie

## JAN SCHEJBAL

Senior Scientist I - Proteomics, OTAS -Quantitative, Translational and ADME Sciences, Abbvie

#### JAN TOMLINSON

Patient Research Advocate, I-Spy Trial

#### **JANA LIPKOVA**

Assistant Professor, Pathology & Laboratory Medicine, University of California, Irvine

### JANET JIN

Executive Director, Clinical Imaging and Diagnostics, Amgen

#### **IESUS MENDOZA MAGBANUA**

Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco

#### **IOHN SNOWBALL**

Senior Scientist, Procter & Gamble

### **JOSHUA J. LEVY**

Director of Digital Pathology Research, Assistant Professor of Pathology and Computational Biomedicine, Cedars Sinai **Medical Center** 

#### **KOICHI HASHIKAWA**

Principal Scientist Computational, Johnson & Johnson Innovative Medicine

#### **LAURENT AUDOLY**

CEO, Co-Founder, PriveBio, Inc.

#### **LEROY HOOD**

Co-Founder, Institute of Systems Biology

#### **LOKESH AGRAWAL**

Chief (Acting), iorepositories and Biospecimen Research Branch (BBRB); Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

#### MIKE MONTALTO

Vice President, Precision Medicine, Global Development, Amgen

## NATÁLIA FARAJ MURAD

Bioinformatics Specialist, University of California, San Francisco

Welcome

Highlights

Special Event **Features** 

**Sponsors** 

Agenda At A Glance

Speakers

**FULL** PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information







#### **ALL PROGRAMMES**

## **Confirmed Speakers**



Highlights

Special Event **Features** 

Agenda At A

Speakers

**Sponsors** 

Glance

PROGRAMME:

27 Oct, 2025

28 Oct, 2025

Information









#### **OLIVIER HARISMENDY**

Vice President, Translational Data Science, Zentalis Pharmaceuticals

#### SAM M. HANASH

Co-Director, Department of Center for Global Cancer Early Detection, The University of Texas MD Anderson Cancer Center

#### SATYA SAXENA

Director, Global Proteomics Clinical Pharmacology & Translational Medicine Neurology Business Group, Eisai

#### **SERGEY NOVITSKIY**

Principal Scientist, Amgen

#### **SILAS MANIATIS**

Associate Director, Spatial Genomics, New York Genome Centre

#### **STEPHEN BYERS**

Professor & Associate Director, Lombardi Comprehensive Cancer Center, Georgetown University

#### **SUDESHNA FISCH**

Former Director, Translational Clinical Sciences, Pfizer

#### **SUZANNE COBERLY**

Scientific Senior Director, Senior Director Research Pathology, Protein Homeostasis TRC, Bristol Meyers Squibb

#### **TAMMIE YEH**

Senior Director and Head of Oncology Clinical Biomarkers, Oncology and Cell Therapy, Takeda Pharmaceuticals

#### **TOWIA LIBERMANN**

Director of Genomics – Proteomics Core, Beth Israel Deaconess Medical Center

#### **KHYATI SHAH**

Manager, Translational Oncology Lead, Pfizer

#### **VICKI PLAKS**

Senior Scientific Director, Head of Cell Therapy, Oncology Translational Research, Johnson & Johnson

#### **VLADIMIR ROUDKO**

Director, Advanced Translational Programs, AstraZeneca

#### W. DEAN WALLACE

Professor of Pathology, University of Southern California Keck School of Medicine

#### YASSER RIAZALHOSSEINI

Associate Professor & Head of Cancer Genomics, McGill University

#### YESIM GOKMEN POLAR

Associate Director, Pathology Cancer Program, Emory University School of Medicine

#### **ZHENG AO**

Principal Scientist, Obsidian Therapeutics

#### **ZOLTAN LASZIK**

Director of Digital Pathology, UCSF

SI WU, Senior Principal Scientist, Amgen

**BRYAN DOWNIE**, CEO, Node Biosciences

MANAL MEHIBEL, Associate Scientific Director, AbbVie

KAHKESHAN HIJAZI, Senior Expert II Data Science, Novartis

MANOJ KANDPAL, Director of Research Bioinformatics, Rockefeller University

**ERICA XIN TONG,** Senior Manager, Takeda

MICHAEL WASHBURN, Executive Director, Head of Integrative Sciences: Oncology Translational Medicine, GSK

SHIYA SONG, Senior Principal Scientist, Amgen

**SUSMITA DATTA, Co-Director, Biostatistics &** Epidemiology, University of Flordia





## Day One | 27 October 2025

**Registration Opens** 

**Oxford Global's Welcome Address** 

#### Plenary Keynote Address: The Synergy Of Data-Driven Health And Data-Driven Peptide Drug Discovery

Data-driven health employs a genome and longitudinal phenome analysis of each of many individuals to decipher their individual biological complexities and turn these insights into actionable possibilities to optimize wellness and healthy aging, to avoid disease and to gain causal insights into wellness and disease. Peptide drug discovery will employ large scale DNA synthesis to generate millions of peptide genes and then use the tools to cell and molecular biology to interrogate them individually through phenotypic and targeted selection. I will discuss these two approaches to healthcare and their synergies.

LEROY HOOD, Co-Founder, **Institute of Systems Biology** 

**BIOMARKERS & PRECISION MEDICINE** 

**CONFERENCE ROOM 2:** IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES

Track Chair: Satya Saxena Director, Global Proteomics Clinical Pharmacology & Translational Medicine Neurology Business Group, Eisai

SPATIAL BIOLOGY FOR PRECISION MEDICINE

CONFERENCE ROOM 3:SPATIAL MULTI-OMICS TECHNIQUES & **APPROACHES** 

Track Chair: Elsa Flores. Associate Center Director, Basic Science, Moffitt Cancer Center

**CONFERENCE ROOM 4:** SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION

Track Chair: BRYAN DOWNIE. CEO. Node *Therapeutics* 

Track Chair: TBA

**Track Keynote Address: Evolution** Of Biomarkers In Liquid Biopsies To **Inform Right Dose And Right Patient** 

CONFERENCE ROOM 1: BIOMARKERS

FOR DIAGNOSTIC & CLINICAL

**DEVELOPMENT & REGULATIONS** 

Track Chair: Anuraag Shrivastav, Professor,

University of Winnipeg

Circulating free (cf) and tumor (ct) DNA are used across stages of medicine clinical development to inform dose, identify right patients and guide patient treatments. The emerging uses of cf/ctDNA in clinical development include molecular response for dose selection, minimal residual disease and baseline characterization for patient selection. While Oncology trials often implement ctDNA, the data outside of Oncology is emerging.

MICHAEL WASHBURN, Executive Director, Head of Integrative Sciences: Oncology Translational Medicine, **GSK**  **Track Keynote Address:** 

**Multiomics Approaches For Biomarker Discovery In The Immunotherapy** 

Multiomics approaches integrating genomics, transcriptomics proteomics and spatial data are curial for biomarker discovery in immunotherapy. This presentation will highlight how integration of different modalities identify predictive and prognostic biomarkers using trial data derived from IO combination with TKI. We will explore these modalities to enhance our understanding of MoA, therapeutic efficacy, help in patient stratification and treatment response prediction.

VLADIMIR ROUDKO, Director, Advanced Translational Programs, AstraZeneca

**Conference Room 4** 

Track Keynote Address: Decoding The p53 Pathway: Spatial Multi-Omics Approaches To Unravel Tumor Suppression, Metabolism, And Therapy Resistance

TP53 has long been known as an "undruggable" target due to its fundamental roles in controlling key cellular functions and its role as a transcription factor. The goal of my laboratory is to develop novel methods to target p53 and other "undruggable" pathways therapeutically. We have begun to understand the intricate network of non-coding RNAs regulated by the p53 family and have used high throughput RNA-seg and ChIP-seg to reveal non-coding RNA and other epigenetic regulation of the p53 family pathway in cancer. We have also incorporated machine learning algorithms using digital pathology and spatial transcriptomics, proteomics, and metabolomics to build a spatial understanding of tumor heterogeneity, progression, and therapy resistance (NPJ Precision Oncology, 2023). We will discuss the latest development in biomarker identification using spatial technologies of tumor progression and therapy resistance of p53 altered cancers. These strategies can be further employed to target other "undruggable" tumor suppressor genes and pathways in cancer.

ELSA FLORES, Associate Center Director, Basic Science, Moffitt Cancer Center **Track Keynote Address: AI-Powered Pathology In The Continuum Of Translational And Precision Medicine** 

DIGITAL PATHOLOGY & AI

**CONFERENCE ROOM 5:** 

COMPUTATIONAL PATHOLOGY & AI

Digital Pathology and Al Applications are emerging rapidly in both Pharmaceutical Drug Development through to healthcare applications. This talk will explore the critical need of biomarkers from early through late drug development and the role Al-powered pathology can play throughout this continuum. We will further explore the importance of commercial adoption and availability to Pharma's view on implementation in prospective trials for CDx applications.

MIKE MONTALTO, Vice President, Precision Medicine Global Development, Amgen

**Customized Clinical Flow Cytometry: Agile Solutions For Complex Trials** 

**DISCOVERY** 

Clinical trials demand speed, flexibility, and deep scientific insight. Discovery Life Sciences' Clinical Flow Cytometry team delivers agile, customized assay development—even for complex vaccine, immunotherapy, and cell therapy trials. With cutting-edge spectral cytometry, advanced analytics, and responsive collaboration, we help sponsors overcome delays, boost clarity, and reach critical milestones faster. Join us to accelerate your path to success.

**Solution Provider Presentation** 

**KANVAS** 

**Solution Provider Presentation** 

Q&A session & transition time between conference rooms

GENOMICS

**Diamond/Platinum Level Solution** Provider

> For sponsorship opportunities please contact sponsorship@oxfordglobal.com

NICK JONES, VP Clinical Flow Cytometry, **Discovery Life Sciences** 

Senior Representative, Kanvas Biosciences

Senior Representative, 10x Genomics





Welcome

Highlights

Special Event **Features** 

Sponsors

Agenda At A Glance

**Speakers** 

**FULL** PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information

## Day One | 27 October 2025

**BIOMARKERS & PRECISION MEDICINE** 

SPATIAL BIOLOGY FOR PRECISION MEDICINE

DIGITAL PATHOLOGY & AI

CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL **DEVELOPMENT & REGULATIONS** 

**CONFERENCE ROOM 2:** IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES

CONFERENCE ROOM 3:SPATIAL MULTI-OMICS TECHNIQUES & **APPROACHES** 

**CONFERENCE ROOM 4:** SPATIAL BIOINFORMATICS, DATA **ANALYTICS & INTERPRETATION** 

**CONFERENCE ROOM 5:** COMPUTATIONAL PATHOLOGY & AI

10:05

11:25

1-2-1 Meetings x4



🥏 MORNING BREAK & REFRESHMENTS 🥏



Poster Displays



**Driving Drug Development With Integrated Multi-Omic Insights: Unlocking Precision Medicine With Biodesix' Comprehensive Service** Offerings



This presentation will highlight how integrated multi-omic approaches accelerate therapeutic discovery and development. It will describe Biodesix's end-to-end service capabilities that streamline complex translational workflows, enabling the generation of high-resolution, actionable data. These data empower precision medicine strategies, providing deeper biological insights and supporting more effective therapeutic decision-making.

**Delivering Spatial Pathology At Scale** 



Learn about the world'd first high throughput spatial instrument - combining RNA and Protein at subcellular resolution.

**Subcellular Multi-Omic Imaging Of The Entire Protein-Coding Transcriptome: Technology To Discover Biomarkers** That Really Work!



CosMx WTX images the whole transcriptome at subcellular resolution to uncover complete pathway biology. GeoMx DPA profiles 1200+ proteins with single-cell precision for unmatched multiomics to enable biomarker development from FFPE tissue.

**Unlocking Neuroscience Applications In Spatial Omics** 



SPATIAL offers browser-based access to ariadne.ai's best-in-class models for cell and tissue segmentation, artifact suppression and marker positivity mapping. In this presentation, we'll focus particularly on the applications that precise cell segmentation unlocks in neuroscience, and the use of scalable elastic registration in sequential chromogenic IHC.

**Gold Level Solution Provider Presentation** 

> For sponsorship opportunities please contact sponsorship@oxfordglobal.com

JOHN MANUEL, Spatial Science & Technology Advisor, **Singular Genomics** 

JOSEPH BEECHEM, Chief Scientific Officer, SVP of R&D, Bruker Spatial **Biology** 

FABIAN SVARA, CEO, Ariadne Al

Speakers

MATTHEW PINK, Vice President, Business Development **Biodesix** 

Q&A session & transition time between conference rooms

**Applying Novel Biomarker Technologies To Enable Precision Medicine Driven Clinical Development And Patient Management** 

Advances in precision medicine are reshaping clinical development and patient management by enabling data-driven, biomarker-guided decision-making and the delivery of targeted therapeutic interventions. Emerging technologies such as epigenomics, liquid biopsies, and Al-powered analytics are accelerating biomarker discovery and enhancing the sensitivity, specificity and accuracy of biomarker detection. Realizing the full potential of these innovations in patient management, however, will require the development of novel regulatory frameworks and pathways to support clinical implementation

**Patient Focused Drug Development** For Parkinson's Disease

Early intervention strategies are key to halting the relentless progression of brain diseases. Biomarker informed clinical trials are now emerging across a range of neurological diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease and ALS. This presentation will highlight the role of precompetitive global collaborations to advance the regulatory maturity of biomarkers to support innovative treatments for neurodegenerative diseases.

DIANE STEPHENSON, Vice President, Neurology; Executive Director, Critical Path for Parkinson's, Critical **Path Institute** 

**Single-Cell Transcriptome Approaches** 

**From Computational Pathology To Spatial Transcriptomics: Our Evolving Strategy In Support Of Oncology Drug** Development

In the era of precision medicine, the integration of advanced technologies into oncology drug development is essential for improving patient outcomes and accelerating therapeutic discovery. This presentation outlines our strategic evolution from the application of computational pathology—leveraging Al-driven image analysis and digital histopathology—to the incorporation of spatial transcriptomics, a transformative approach that combines gene expression profiling with spatial context. We will highlight how this progression enhances our ability to interrogate tumor heterogeneity, understand the tumor microenvironment, and identify spatially-resolved biomarkers. Case studies will demonstrate how these methodologies are being operationalized within translational research pipelines, informing target identification, patient stratification, and biomarker-driven clinical trials. Through this integrated framework, we aim to bridge the gap between pathology and molecular profiling, driving a more informed, data-rich approach to oncology drug development.

VLADIMIR ROUDKO, Director, Advanced Translational Programs, AstraZeneca

**Redefining The Role Of The Pathologist** With Digital Pathology And Al

At UTMB we are fully digital for primary pathology diagnosis and routinely use validated Al models to detect prostate and breast cancer. We are harnessing Generative AI to produce personalized integrative diagnostic reports. Finally, we use Al to query EMR and lab data to identify high risk patients for appropriate interventions, improving care while enhancing revenue across the health system.

HARSH THAKER, Professor and Chair ad interim, Department of Pathology, **University of Texas Medical Branch -**

JANET JIN, Executive Director, Clinical Imaging and Diagnostics Clinical Biomarker and Diagnostics, Amgen

SILAS MANIATIS, Associate Director, Spatial Genomics, New York Genome Center

Galveston

Welcome

Highlights

Special Event **Features** 

Sponsors

Agenda At A Glance

**FULL** PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information





Day Une   27 Uctober 2025					
BIOMARKERS & PRECISION MEDICINE		SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI	
CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT & REGULATIONS	CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES	CONFERENCE ROOM 3:SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES	CONFERENCE ROOM 4: SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION	CONFERENCE ROOM 5: COMPUTATIONAL PATHOLOGY & AI	
Role Of Biospecimen Science And Biobanking In Understanding Precision Medicine In Cancer	Panel Discussion: Challenges In Translating Exploratory Biomarkers Into The Clinic	Panel Discussion: Addressing The Future Needs Of Spatial Multi-Omics	Panel Discussion: Data Sharing And Reproducing Analysis In The World Of Spatial Transcriptomics	Panel Discussion: Building A Business Case For Digital Pathology	
Biospecimens are the essential starting materials for the biomarker assays that enable precision medicine and preanalytical factors can directly influence molecular results from assays conducted for basic research,	Validation and reliability     Standardization & reproducibility     Clinical utility & validation     Overcoming the challenges  Moderator:	Future of spatial biology     Moving towards the practical implementation of spatial findings     How to translate into precision medicine	<ul> <li>How to share images for reuse of data</li> <li>Establishing a set of primary data</li> <li>Use for reproducing analyses and facilitation of computational method development</li> </ul>	Wants and needs from different stakeholders     ROI     Clinical benefits     Efficiency & quality gains	
biomarker discovery, and biomarker validation, and can also influence the development of clinical assays. This talk will focus on role of biospecimen science in context of cfDNA as a predictive, prognostic clinical biomarker, and cover briefly The Cancer MoonshotSM Biobank (moonshotbiobank.cancer.gov), which is a National Cancer Institute (NCI)-sponsored study that aims to accelerate cancer research through the collection of longitudinal liquid biopsy specimens and tissues from patients with advanced cancer receiving standard of care therapy.	SATYA SAXENA, Director, Global Proteomics Clinical Pharmacology and Translational Medicine, Neurology Business Group, Eisai  Panellists: OLIVIER HARISMENDY, Vice President, Translational Data Science, Zentalis Pharmaceuticals TAMMIE YEH, Senior Director and Head of Oncology Clinical Biomarkers, Takeda Pharmaceuticals LAUREN NEVES, Science & Technology Advisor, 10X Genomics	Panellists: JOHN SNOWBALL, Senior Scientist, Procter & Gamble  ALEXANDER KLIMOWICZ, SR Research Fellow, Boehringer Ingelheim  SENIOR REPRESENTATIVE, Miltenyi Biotech  EVAN KELLER, Professor & Director of Single Cell Spatial Analysis Program, University of Michigan  ZHENG AO, Principal Scientist, Obsidian Therapeutics  MANOJ KANDPAL, Director of Research Bioinformatics, Rockefeller University	Panellists:  NATÁLIA FARAJ MURAD, Bioinformatics Specialist, University of California, San Francisco  YASSER RIAZALHOSSEINI, Associate Professor & Head of Cancer Genomics, McGill University  SHIYA SONG, Senior Principal Scientist, Amgen		
LOKESH AGRAWAL, Chief (Acting), iorepositories and Biospecimen Research Branch (BBRB); Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute	ERICA XIN TONG, Senior Manager, <b>Takeda</b> INTERACTIVE	Bioinformatics, Rockelener University	J	INTERACTIVE	
Navigating Regulatory Challenges In Combined Trials: Drug And IVD Integration An An Evolving Landscape	Targeted Therapeutics In Fibroinflammatory Diseases - A Precision Medicine Framework			Computational Pathology Apps Deployment & Challenges - Integration With Existing Workflows And Hardare/Software Set-Ups	
In the rapidly evolving regulatory landscape, the integration of drugs and in vitro diagnostics (IVDs) in combined trials presents unique challenges and opportunities. This presentation will explore the regulatory hurdles and implications associated with these trials, focusing on the impact of the US FDA's Laboratory Developed Test (LDT) final rule, the European Union's In Vitro Diagnostic Regulation (IVDR), and the regulatory requirements in the Rest of the World (ROW). Attendees will gain insights into the complexities of sample testing and the strategies to navigate these regulatory frameworks effectively.	PriveBio is a precision medicine biotech focused on discovering and developing novel medicines to cure fibro-inflammation in cardiometabolic, renal diseases and obesity that address unmet medical need in the post-GLP1 era. Powered by proprietary high dimensionality patient-derived data, the company is developing a portfolio of first-inclass therapeutics and blood-based detection assays to deliver impact for patients as efficiently as possible.				
HONGDA ZHAO, Director of Precision Medicine and Digital Health in Global Regulatory Sciences, <b>BMS</b>	LAURENT AUDOLY, CEO, Co-Founder, <b>PriveBio, Inc</b>	INTERACTIVE	INTERACTIVE	ZOLTAN LASZIK, Director of Digital Pathology, <b>UCSF</b>	

12:40



Welcome

Highlights

Special Event Features

Sponsors

Agenda At A Glance

Speakers

FULL PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information





1:35

2:35



Welcome

Highlights

Special Event Features

Sponsors

Agenda At A Glance

Speakers

FULL PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information



Day One   27 October 2025					
BIOMARKERS & PRECISION MEDICINE		SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI	
CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT & REGULATIONS	CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES	CONFERENCE ROOM 3:SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES	CONFERENCE ROOM 4: SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION	CONFERENCE ROOM 5: COMPUTATIONAL PATHOLOGY & AI	
Innovative Diagnostic Solutions: Maximizing Opportunities In Bladder Cancer Treatment  Bladder cancer is the sixth most common cancer in the US, with ~75% of newly diagnosed patients classified as non-muscle invasive bladder cancer (NMIBC). Current medical practice provides an opportunity for novel targets, innovative therapeutics and development of a robust precision medicine strategy. TAR-210 is an intravesical Drug Releasing System (iDRS) under investigation for treatment of certain FGFRalt-positive patients. NMIBC offers unique opportunities for diagnostics, including standard tissue testing, urine-based liquid biopsy, and computational pathology.	ECG-AI Enabled Cardiorenal Risk Prediction: A Methodological Use- Case For Biomarker-Driven Trial Enrichment Strategy	Multiomic Modular Network Approach For Target ID, Patient Stratification & Combo Rationale In IBD   Gene module network is deconstructed using scRNAseq data from IBD patient samples. Highly multiplexed spatial omics approach (CosMx) recapitulated granular cell types in space. Spatial domain (niche) highlighted unique spatial interactions in IBD	<ul> <li>Applying Spatial Analytics To Urologic Cancers</li> <li>Spatial analytics offers multiple opportunities to incorporate spatially-derived parameters as biomarkers.</li> <li>Multiple methods exist to analyze spatially-derived parameters including spatial localization of transcript signatures, cell to cell distance, and cellular niche formation.</li> <li>These methods will be demonstrated in urologic cancers.</li> </ul>	Foundational Models For Survival Prediction In Oncology  Foundational models enable learning from unlabeled data & fine-tuning with minimal labeled samples- improving accuracy, generalizability, & reducing bias. However, most FMs are tested on simple classification tasks, while prognostic prediction- where labeled data are scarce- remains underexplored. We benchmark 10 recent FMs across 4 consortia for survival prediction in oncology, evaluating performance, generalization, & interpretability. We found that multimodal FMs can learn general cancer hallmarks & deliver robust predictions, even for rare diseases & cancers unseen during training highlighting their	
DAVID WEINGEIST, Scientific Director, Oncology Precision Medicine & Diagnostics, <b>Johnson &amp; Johnson</b> Innovative Medicine	SUDESHNA FISCH, Former Director, Translational Clinical Sciences, <b>Pfizer</b>	KOICHI HASHIKAWA, Principal Scientist Computational, <b>Johnson &amp; Johnson Innovative Medicine</b> Q&A session & transition time between conference rooms	EVAN KELLER, Professor & Director of Single Cell Spatial Analysis Program, <b>University of Michigan</b>	JANA LIPKOVA, Assistant Professor, Pathology & Laboratory Medicine, University of California, Irvine	
Femtogram Precision in a Forest of Noise: Advancing Ultra-Sensitive	Smaller Trials, Faster Answers, Unexpected Benefits: Proteomics	Characterizing The Tumor Microenvironment In Clinical Trials	Spatial Proteomics For Biomarker Discovery: Mapping Tissue	Automated and Scalable Solutions For Building Digital Pathology Datasets	
Advances in immunoassay technologies fuel biomarker research. The new FemtoQuest™ system offers a suite of assays with femtogram/mL sensitivity in dual and single plex formats. We will discuss high sensitivity detection in neurodegenerative disease.	SomaSignal™ Tests (SSTs) are redefining how drug efficacy and safety are evaluated. Using clinical trial data, we'll demonstrate how RUO SSTs detect changes in risk and health status across drug classes, enabling faster insights and fewer participants.	By Combining 17-plex Fluorescent Immunohistochemistry & Cellular Neighborhood Analyses  RARECYTE  Understanding the intricacies between tumor microenvironments (TMEs) and immune cell infiltrates is critical for designing nextgeneration, immune-modulating therapies. We validated a clinical grade, 17-plex tumor immune landscape assay to characterize T-cells, B-cells, myeloid cells, plasma cells, and tumor cells across five major cancer types using the OrionTM platform. The panel design includes nine immune, five functional/ checkpoint and three structural markers. The assay was found to be reproducible across staining runs for all biomarkers when tested on non-small cell lung cancer, breast carcinoma, colorectal cancer, prostate cancer and melanoma formalin-fixed, paraffin embedded tissue sections. Resulting OrionTM images were analyzed to generate cell phenotypes and the TME was characterized using cellular neighborhoods using spatial cellular graph partitioning (SCGP) on the segmented fluorescent immunohistochemistry (FIHC) data. We identified twelve TMEs within the analyzed cancer samples with our validated, 17-plex FIHC assay. We expect these novel algorithms to be useful for gaining new insights into tumor biology and tissue/immune architecture, aiding the development of next-generation Immuno-	Architecture To Advance Translational Research & Precision Medicine   Discover how the PhenoCycler-Fusion and our 1060 and neuroscience ultrahigh-plex panels accelerate biomarker discovery and bring spatial biology capabilities to translational researchers focused on positive therapeutic outcomes.	Innovations in machine learning and automated image analysis have created a new frontier for biomarker discovery based on histological tissue sections. Generating datasets to interrogate requires a sample preparation pipeline that allows for high-throughput tissue staining and imaging while minimizing sample-to-sample variance and scan time. From tissue embedding to image analysis, Leica Biosystems provides a portfolio of solutions, including the new Aperio FL 120 and Aperio GT 180 scanners that enable digital pathology for research applications.	
LINDA MEEH, Ph.D. Segment Head – Immunoassay Platform Solutions, <b>Millipore Sigma</b>	STEPHEN WILLIAMS, MD, PhD, Chief Medical Officer, <b>Standard BioTools</b>	Oncology therapies.  JENNIFER BORDEAUX, PhD., Navigate BioPharma Services, Inc., a Novartis Subsidiary	CLEMENS DUERRSCHMID, PhD, Manager of Field Application Scientists, <b>Quanterix</b>	ERICA PAWLAK, Ph.D., Solutions Architect, <b>Leica Biosystems</b>	

3:25

Welcome

Highlights

Special Event Features

Sponsors

Agenda At A Glance

Speakers

FULL PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information

**Book Now** 





## Day One | 27 October 2025

BIOMARKERS & PRECISION MEDICINE		SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI	
	CONFERENCE ROOM 1: BIOMARKERS FOR DIAGNOSTIC & CLINICAL DEVELOPMENT & REGULATIONS	CONFERENCE ROOM 2: IDENTIFICATION, QUALIFICATION, & VALIDATION OF BIOMARKERS IN TRANSLATIONAL STUDIES	CONFERENCE ROOM 3:SPATIAL MULTI-OMICS TECHNIQUES & APPROACHES	CONFERENCE ROOM 4: SPATIAL BIOINFORMATICS, DATA ANALYTICS & INTERPRETATION	CONFERENCE ROOM 5: COMPUTATIONAL PATHOLOGY & AI
	What Do Clinical Biomarkers Bring To The Table?	Biomarker Discovery And Strategy For Rare Disease Drug Development	Landscaping Next Generation Spatial Platforms Utilizing Hair Follicle Niche	Using Spatial Omics To Refine Cancer Diagnosis	Digitizing Your Biospecimen Repository: Why, How And When?
)	Dr. Yeh will be presenting an overview on the value and utility of including biomarkers in clinical trials despite the additional resources and complexities that are introduced. She will also share specific case examples showing how clinical biomarkers have influenced and impacted specific oncology clinical trials, ranging from patient selection to end-of-treatment sample analyses to inclusion as a primary endpoint.	Drug development for rare diseases presents unique challenges, including small patient populations, clinical and genetic heterogeneity, limited natural history data, and a scarcity of nonclinical and clinical studies. At Ultragenyx, we have implemented an integrated biomarker strategy across our development pipeline. Established biomarker assays are employed in multiple preclinical and clinical studies to elucidate disease mechanisms, assess pharmacodynamic responses, inform dose selection, and support decision-making throughout the development process.	<ul> <li>Spatial transcriptomics enables the understanding of complex biological systems. It allows one to examine intact biological tissues, answering the elusive question of where, not just what, is happening.</li> <li>However, multiple platforms are available to perform Spatial Transcriptomics. We utilize the hair follicle's spatial complexity to compare and contrast 6 leading Spatial Transcriptomics platforms and provide an overview of our experiences.</li> </ul>		<ul> <li>Effective biorepository collections require labor intensive and costly resources dedicated to patient consenting, specimen processing and biospecimen storage.</li> <li>A weakness of many biorepositories is the frequent underutilized of these specimens. We have developed a highly functional biorepository software that includes digital images of all collected samples to enable rapid review of the material for quicker sample selection and improved utilization.</li> </ul>
	TAMMIE YEH, Senior Director and Head of Oncology Clinical Biomarkers, <b>Takeda Pharmaceuticals</b>	NICOLE DAVIS, Associate Director, Bioanalytical & Biomarker Development, <b>Ultragenyx Pharmaceutical</b>	JOHN SNOWBALL, Senior Scientist,  Procter & Gamble	YASSER RIAZALHOSSEINI, Associate Professor & Head of Cancer Genomics, McGill University	W. DEAN WALLACE, Professor of Pathology, <b>University of Southern</b> <b>California Keck School of Medicine</b>
5	🕏 AFTERNOON NETWORKING BREAK & REFRESHMENTS 🕏				
J		1-2-1 Meetings x4		Poster Displays	
	Attendees Are Welcome To Attend Co-Located Sessions	A Multi-Cancer Stratification Test (MCaST) To Tailor Cancer Screening Based On Personalized Risk Profile	Spatial Transcriptomic Analysis Of Breast Cancer Patients After Endocrine/CDK4/6 Treatments: Deconvoluting The Tumor Microenvironment	Spatial Profiling Of p16+ Microenvironments In Postmenopausal Ovaries Reveals Senescence Signatures With Diagnostic And Therapeutic Potential	Applications Of Al For Prostate Histology
5		Cancer screening at the present time is limited to a few common cancers in the US and is largely based on age. MCaST is a protein based blood test intended to determine risk for nine cancers representing 85% of all cancer diagnoses. The performance and cost effectiveness of MCaST will be presented.	We explored how the tumor microenvironment (TME) affects resistance to CDK4/6 inhibitors in ER+ breast cancer using spatial transcriptomics on tumor samples. Higher levels of immune cells and cancer-associated fibroblasts (CAF) were correlated with progression suggesting the crucial role of TME in driving resistance to CDK4/6 inhibitors. The study identifies potential targets to overcome therapy resistance.	<ul> <li>How spatial transcriptomics can uncover senescent (p16□) cell niches in postmenopausal ovaries and reveal new insights into reproductive aging</li> <li>By integrating histological imaging with molecular data, we identified unique senescence signatures with diagnostic and therapeutic potential</li> <li>I'll walk you through data organization, analysis, and validation across patients — showing how these findings can be robust and clinically relevant</li> </ul>	Pathology and radiology imaging provide complementary information for the diagnosis and prognosis of prostate cancer. This talk discusses techniques for analyzing modalities individually as well as integrating imaging signals with clinical data using modern machine learning methods. Applications include cancer detection, grading, segmentation, and recurrence prediction across multi-institutional datasets.
		SAM M. HANASH, Co-Director, Department of Center for Global Cancer Early Detection, <b>The University of</b> <b>Texas MD Anderson Cancer Center</b>	YESIM GOKMEN POLAR, Associate Director, Pathology Cancer Program, <b>Emory University School of Medicine</b>	NATÁLIA FARAJ MURAD, Bioinformatics Specialist, <b>University of California, San</b> <b>Francisco</b>	COREY ARNOLD, Professor and Vice Chair of Research, Radiology; Professor, Pathology, Bioengineering, and Electrical & Computer Engineering, <b>UCLA</b>
n	Eirocido Chat With Largy Used		Q&A session & transition time between conference room	าร	
U	Fireside Chat With Leroy Hood				

PRECISION MEDICINE

Welcome

Highlights

Special Event Features

Sponsors

Agenda At A Glance

Speakers

FULL PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information

Book Now



LEROY HOOD, Co-Founder, Institute of Systems Biology

6:00

3:50

4:15

5:35

Biomarkers

**Precision Medicine in** 

Moderator: SUDESHNA FISCH,

Former Director, Translational

Clinical Sciences, Pfizer

**Novel Therapeutics** 

- Predictive toxicology models / cross-species toxicity prediction
- · Integration of multi-omics data

Digital Pathology & Al

 Digital pathology workflows including in silico safety profiling Moderator: NEIL PFISTER, Principal Investigator,

University of Alabama at

Birmingham

**Moderator TBA** 

**Separation Of Reverse And Forward Translation** In Pharma: The Case Of **Data Scientists** 

HARISMENDY, Vice President,

Translational Data Science,

Zentalis Pharmaceuticals

**Moderator** OLIVIER

**Advancing Spatial Imaging Techniques in Novel Development Of Drugs** 

Moderator: ABEER OBAID,

Senior Scientist I, AbbVie

**Analysis Using Advanced Spatial Profiling** Techniques

Moderator: ZHENG AO, Principal Scientist, Obsidian Therapeutics

08:05

08:40

## 💋 Plenary Keynote Address - Harnessing Computational Tools In Precision Medicine: Implementation And Future Directions

Achieving precision health will require Al advances spanning biomedical discovery to healthcare delivery. Yet the digital health ecosystem is siloed between discovery and delivery as well as between remote monitoring and in-person clinical care. This talk discusses how digital public utility -- as exemplified by JupyterHealth, an open-source platform that extends Jupyter tools to healthcare – enables real-world precision health solutions.

IDA SIM, Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley); Co-Director, **UCSF UC Berkeley Joint Program in Computational Precision Health** 



Digital Pathology & Al

**Workflows: Enhancer or** 

Take The Lead

The Role of AI In Pathologist

**Replacement? Who Should** 

## **BIOMARKERS & PRECISION MEDICINE** CONFERENCE ROOM 2: BIOMARKER

**Track Keynote:** 

Medicine

**Translational Biomarkers** 

**In Clinical Trials For** 

**Immunotherapy** 

**Moderator:** TOWIA

LIBERMANN, Director of

Genomics - Proteomics

& MULTI-OMIC APPROACHES IN DISCOVERY & CLINICAL DEVELOPMENT FOR PERSONALIZED **TREATMENT** 

**CONFERENCE ROOM 3:** APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN **BIOLOGY** 

**CONFERENCE ROOM 4: IMAGE** ANALYSIS, AI-POWERED IMAGING FOR DIGITAL PATHOLOGY & SPATIAL **BIOLOGY** 

**CONFERENCE ROOM 5:** UTILIZING DIGITAL PATHOLOGY IN PHARMA: DRUG DEVELOPMENT, CLINICAL TRIALS & PERSONALIZED **MEDICINE** 

DIGITAL PATHOLOGY & AI

Track Chair: TBA

Track Chair: Jan Schejbal, Senior Scientist I - Proteomics, QTAS - Quantitative, Translational and ADME Sciences, AbbVie

A Novel Peptide-Driven Proteomics

**Discovery Challenges In Early-Phase** 

**Platform To Overcome Biomarker** 

Biomarkers play a critical role in early

phases of drug development by providing

intended mechanism of action of the drug

in human systems. Here, we describe the

utility of an orthogonal network-informed

strategy to facilitate the identification of

Phase clinical trial samples.

potential mechanism of action (MoA) and

pharmacodynamic (PD) biomarkers in Early-

unbiased peptide-driven global proteomics

evidence of biological engagement and

**Track Keynote:** 

Clinical Trials.

**CONFERENCE ROOM 1:** 

TECHNOLOGIES FOR BIOMARKER

**ANALYSIS** 

Track Chair: Anuraag Shrivastav, Professor, University of Winnipeg

The Convergence: Multi-Omics, AI,

Pharma's move towards multimodal omics

+ Al paradigms to drive precision medicine

development: Yesterday, today and tomorrow

strategies and actionable trial insights

Transformative applications in clinical

Future horizons: Foundation models,

opportunities, and challenges

& The Next Horizon Of Precision

Track Chair: TBA

**Track Keynote:** 

Spatial multiomics is transforming

our ability to decode the complexity

of human cancers by mapping tumor

and stromal interactions in situ. I will

highlight advances from our work in

gynecologic cancers, including insights

into therapy resistance and response,

and discuss how spatial analyses

oncology strategies

of patient samples can reveal novel

biological targets and guide precision

Track Chair: TBA

**Track Keynote:** 

**Track Keynote: High throughput Multiplexed IHC Decoding Tumor Microenvironments** With Spatial Technologies **Imaging Of Cleared Human Brain** 

SPATIAL BIOLOGY FOR PRECISION MEDICINE

Tissue-clearing combined with immunostaining affords the ability to map cellular-level structures within large, intact tissue samples. However, imaging can be prohibitively slow, repetitive staining is almost impossible and resulting datasets are huge. I will present methods that enable ultra-high throughput light-sheet imaging, combined with multiplexed immunostaining strategies that can enable single-pass, high-content imaging of samples including the whole human brain.

From Glass to Data: Computational **Pathology driving Precision Medicine** 

As precision medicine advances, the integration of pathology data with molecular and clinical insights offers the unique opportunity to deeply understand disease biology and guide therapeutic decisions. At Johnson and Johnson, we are building a global digital pathology ecosystem that combines high resolution imaging, Al- driven analytics, and multi-omics integration to accelerate both drug development and clinical translation. Through case studies, this presentation will highlight how computational pathology is transforming our approach to biomarker discovery, patient risk stratification and companion diagnostic development across oncology.

SATYA SAXENA, Director, Global Proteomics Clinical Pharmacology and Translational Medicine, Neurology Business Group, Eisai

AMRITA PATI, Executive Director, **Precision Medicine Computational** Biology, Amgen

ANIL SOOD, Professor & Vice Chair for Translational Research, Co-Director of the Center for RNA Interference and Non-Coding, MD Anderson Cancer Center

ELIZABETH HILLMAN, Chair, Department of Imaging Sciences, Endowed Chair and Member, St Jude Children's Research Hospital

GUNEET WALIA, Senior Director, Data Science & Digital Health, Johnson & **Johnson Innovative Medicine** 

Welcome

Highlights

Special Event **Features** 

Sponsors

Agenda At A Glance

Speakers

**FULL** PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information

**Book Now** 









09:10

## Day Two | 28 October 2025

**BIOMARKERS & PRECISION MEDICINE** 

SPATIAL BIOLOGY FOR PRECISION MEDICINE

DIGITAL PATHOLOGY & AI

**CONFERENCE ROOM 1:** TECHNOLOGIES FOR BIOMARKER **ANALYSIS** 

CONFERENCE ROOM 2: BIOMARKER & MULTI-OMIC APPROACHES IN DISCOVERY & CLINICAL DEVELOPMENT FOR PERSONALIZED **TREATMENT** 

**CONFERENCE ROOM 3:** APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN **BIOLOGY** 

CONFERENCE ROOM 4: IMAGE ANALYSIS, AI-POWERED IMAGING FOR DIGITAL PATHOLOGY & SPATIAL **BIOLOGY** 

**CONFERENCE ROOM 5:** UTILIZING DIGITAL PATHOLOGY IN PHARMA: DRUG DEVELOPMENT, CLINICAL TRIALS & PERSONALIZED MEDICINE

**Diamond Level Solution Provider Presentation** 

> For sponsorship opportunities please contact sponsorship@oxfordglobal.com

> > Olink

Senior Representative,

Olink

**Diamond Level Solution Provider** Presentation

> For sponsorship opportunities please contact sponsorship@oxfordglobal.com

Image Analysis and Al-Powered **Imaging for Digital Pathology & Spatial Biology** 

> PRECISION for medicine

Al and ML methods such as graph neural networks (GNNs) can be applied to histopathology-based expression technologies, eg, IHC and mIF to discover spatial relationships that correlate with clinical response, bystander effect and patient outcomes.

DARREN DAVIS - Senior Vice President,

Global Digital Pathology, Genomics &

Liquid Biopsy Solutions, **Precision For** 

**Diamond/Platinum Level Solution Provider Presentation** 

> For sponsorship opportunities please contact sponsorship@oxfordglobal.com

**Diamond/Platinum Level Solution Provider Presentation** 

> For sponsorship opportunities please contact sponsorship@oxfordglobal.com

09:35

10:00

**Solution Provider Presentation** 

11:20

MORNING BREAK & REFRESHMENTS 🥏



1-2-1 Meetings x4

SYNCELL

Medicine





Lung cancer diagnostics face a critical challenge: maximizing limited tissue samples while maintaining accuracy. Our proof-ofconcept study demonstrates how multiplex immunofluorescence transforms this challenge into opportunity and integrates into existing clinical workflows. By consolidating multiple diagnostic markers into a single streamlined assay, we achieved high diagnostic concordance with traditional methods while preserving precious tissue for molecular testing. This spatial biology approach provides enhanced quantitative capabilities and comprehensive tumor profiling on a single slide. As precision medicine advances with new targeted therapies, this technology bridges the gap between cutting-edge spatial biology and practical clinical impact, ultimately improving patient outcomes through smarter diagnostics.

CARLO BIFULCO, Medical Director of Cancer Genomics & Precision Oncology Providence Cancer Institute and Chief Medical Officer, Providence Genomics **Gold Level Solution Provider** 

Presentation

For sponsorship opportunities please contact sponsorship@oxfordglobal.com

Poster Displays

**Gold Level Solution Provider** Presentation

Œ

For sponsorship opportunities please contact sponsorship@oxfordglobal.com

Senior Representative, Syncell

Q&A session & transition time between conference rooms



Welcome

Highlights

Special Event **Features** 

Sponsors

Agenda At A Glance

**Speakers** 

FULL PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information





Day Two   28 October 2025					
BIOMARKERS & PRECISION MEDICINE		SPATIAL BIOLOGY FOR PRECISION MEDICINE		DIGITAL PATHOLOGY & AI	
CONFERENCE ROOM 1: TECHNOLOGIES FOR BIOMARKER ANALYSIS	CONFERENCE ROOM 2: BIOMARKER & MULTI-OMIC APPROACHES IN DISCOVERY & CLINICAL DEVELOPMENT FOR PERSONALIZED TREATMENT	CONFERENCE ROOM 3: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY	CONFERENCE ROOM 4: IMAGE ANALYSIS, AI-POWERED IMAGING FOR DIGITAL PATHOLOGY & SPATIAL BIOLOGY	CONFERENCE ROOM 5: UTILIZING DIGITAL PATHOLOGY IN PHARMA: DRUG DEVELOPMENT, CLINICAL TRIALS & PERSONALIZED MEDICINE	
Aptamer-Based 11k SomaScan Proteomics Driving Non-Invasive Biomarker Discovery and Precision Medicine	Utilizing Multi-Omics Data To Ensure Clinical Utility Of Tests	Spatial Multi-Omics: Mapping Immune Landscapes in Respiratory Disease	Combining 3D Tissue Imaging With Multi-Modal Spatial Analysis For Cell Therapy Pre-Clinical Development	Tissue-Based Imaging and Analytical Workflows: Unlocking Target Biology Insights In Early-Phase Clinical Trials	
Novel proteomics platforms have been developed to drive precision medicine and biomarker discovery. We will present our efforts on non-invasive biomarkers for a broad range of clinically highly relevant diagnostic, predictive, and prognostic indications (oncology, autoimmune diseases, neurodegenerative diseases) using the currently most comprehensive, high throughput proteomics platform, SomaScan v5.0, measuring 11,000 proteins.				This presentation explores advanced tissue-based imaging and analytics in early-phase clinical trials, highlighting innovations that enable precise biomarker identification. Through case studies, we'll show how iterative analysis pipelines enhance translational research and decision-making. We'll also address challenges in complex study analysis and strategies for implementing scalable, reproducible imaging solutions that accelerate discovery-to-clinic translation.	
TOWIA LIBERMANN, Director of Genomics – Proteomics Core, <b>Beth</b> <b>Israel Deaconess Medical Center</b>	EUGEAN JIWANMALL, Senior Research Analyst for Medical Policy & Technology Assessment, <b>Independence Blue Cross</b>	ALEXANDER KLIMOWICZ, SR Research Fellow, Immunology & Respiratory Disease Research, <b>Boehringer</b> <b>Ingelheim Pharmaceuticals</b>	ZHENG AO, Principal Scientist, <b>Obsidian Therapeutics</b>	ABHISHEK AGGARWAL, Director, Pathobiology, <b>Gilead</b>	
		Q&A session & transition time between conference rooms			
LEVITAS BIO	Solution Provider Presentation  Mission bio	Solution Provider Presentation  Lead ENABLE MEDICINE	Creative Solutions To Scientific & Technical Challenges In Digital Pathology  CONCEPT LIFE SCIENCES  MINISTER SCIENCES	Silver Level Solution Provider Presentation  For sponsorship opportunities please contact sponsorship@oxfordglobal.com	
			Image analysis is a key step in Spatial Biology but presents common challenges.  We address two typical issues to support drug development and biomarker discovery.  Our method enables collagen fiber orientation analysis on existing stained histology samples, with no additional staining or imaging required. Improved marker detection and data consistency in variably stained samples supports scalable studies.		
Senior Representative, <b>Levitas Bio</b>	ERIN CROWGEY, Director of Translational Medicine, <b>Incyte</b>	Senior Representative, Enable Medicine	GIULIA TAGLIAVINI, Senior Scientist, Concept Life Sciences		

12:10



Welcome

Highlights

Special Event Features

Sponsors

Agenda At A Glance

Speakers

FULL PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information





## Day Two | 28 October 2025

**BIOMARKERS & PRECISION MEDICINE** 

SPATIAL BIOLOGY FOR PRECISION MEDICINE

DIGITAL PATHOLOGY & AI

**CONFERENCE ROOM 1:** TECHNOLOGIES FOR BIOMARKER ANALYSIS

CONFERENCE ROOM 2: BIOMARKER & MULTI-OMIC APPROACHES IN DISCOVERY & CLINICAL **DEVELOPMENT FOR PERSONALIZED TREATMENT** 

CONFERENCE ROOM 3: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY

**CONFERENCE ROOM 4: IMAGE** ANALYSIS, AI-POWERED IMAGING FOR DIGITAL PATHOLOGY & SPATIAL BIOLOGY

**CONFERENCE ROOM 5:** UTILIZING DIGITAL PATHOLOGY IN PHARMA: DRUG DEVELOPMENT, CLINICAL TRIALS & PERSONALIZED MEDICINE

**Conference Room 1: Panel Discussion Application and Integration Of Proteomic Biomarkers In Precision Medicine** 

- Biomarker discovery
- Diagnostics & prognostics
- · Patient stratification & precision medicine

TOWIA LIBERMANN, Director of Genomics - Proteomics Core, Beth Israel **Deaconess Medical Center** 

#### Panellists:

IAN SCHEIBAL, Senior Scientist I – Proteomics, OTAS – Quantitative, Translational and ADME Sciences, AbbVie

SATYA SAXENA, Director, Global Proteomics, Clinical Pharmacology and Translational Medicine Neurology Business Group, Eisai

SAM HANASH, Co-Director, Department of Center for Global Cancer Early Detection, MD Anderson Cancer Center

LOKESH AGRAWAL, Chief (Acting), Biorepositories and Biospecimen Research Branch (BBRB); Cancer Diagnosis Program Division of Cancer Treatment and Diagnosis, National Cancer Institute

## The role of AI in personalized medicine

**Conference Room 2: Panel Discussion** 

**AI-Powered Precision Medicine** 

Challenges of implementing AI in real-world settings

#### Moderated by:

LAURENT AUDOLY, CEO, Co-Founder, PriveBio, Inc

IDA SIM, Professor of Medicine (UCSF) and Computational Precision Health (UCSF and UC Berkeley), UCSF Chief Research Informatics Officer, Co-Director, **UCSF UC Berkeley Joint Program in Computational Precision Health** 

MIKE MONTALTO, Vice President, Precision Medicine, Global Development, **Amgen** 

MANOI KANDPAL, Director of Research Bioinformatics, Rockefeller University

MICHAEL WASHBURN, Executive Director, Head of Integrative Sciences: Oncology Translational Medicine, **GSK** 

**Conference Room 3: Start-Up Zone Pitches** 

10-Minute Presentation:

**UC Berkeley** 

**UC Berkeley** 

10-Minute Presentation:

ions.bio

ions.bio

INTERACTIVE

Track Chair: TBA

#### **LUNCH BREAK & REFRESHMENTS**



Poster Displays



Track Chair: TBA

Track Chair: TBA

FULL **PROGRAMME:** 

Day One

27 Oct, 2025

Day Two

28 Oct, 2025

**Speakers** 

Welcome

Highlights

Special Event

**Features** 

Sponsors

Agenda At A

Glance

**Enhancing Breast Cancer Treatment Decisions With Artificial Intelligence:** A Reliable Approach To Ki-67 Scoring



- Ki-67 is a key breast cancer biomarker in guiding treatment for HR+, HER2- patients. Yet, no consensus exists for its scoring, mainly due to pathologists' variability.
- A Cerba Research conducted comparative study positioned AI as a powerful tool to support breast cancer treatment orientation.

Track Chair: Satya Saxena, Director, Global Proteomics, Clinical Pharmacology and Translational Medicine, Neurology Business Group, Eisai

INTERACTIVE

1-2-1 Meetings x3

**Proteomics Strategies For Parkinson's Disease: Platform Selection & Data** Interpretation



• A comparative look at proteomics platforms for Parkinson's Disease research, guiding decisions on platform selection and approaches to evaluating and integrating resulting data.

**Solution Provider Presentation** 

Track Chair: TBA



**Bronze Level Solution Provider** Presentation



**Bronze Level Solution Provider** Presentation

> For sponsorship opportunities please contact sponsorship@oxfordglobal.com

1:05

MARIE GÉRUS-DURAND, R&D Manager of Histopathology Department, Cerba Research

SCOTT LOHR, SVP Informatics, **Alkahest**, a Grifols Company

Senior Representative, **Elucidate Biotechnologies**  Senior Representative, **Tempus** 

Information

Venue







Welcome

Highlights

Special Event **Features** 

Sponsors

Agenda At A Glance

**Speakers** 

FULL **PROGRAMME:** 

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information

**Book Now** 

**Workshop: Digital Pathology in Pharma - Overcoming Integration Strategies & Future Proofing** 

MEDICINE

- Is the ecosystem ready?
- Digital Pathology as a precision medicine tool

GUNEET WALIA, Senior Director, Data Science & Digital Health, Johnson & Johnson Innovative Medicine

SUZANNE COBERLY, Senior Director Research Pathology, Protein Homeostasis TRC, Bristol Meyers Squibb

KHYATI SHAH, Manager, Translational Oncology Lead, Pfizer

2:55

VICKI PLAKS, Senior Scientific Director, Head of Cell Therapy, Oncology Translational Research, Johnson & **Johnson Innovative Medicine** 

INTERACTIVE

INTERACTIVE

## Day Two | 28 October 2025

BIOMARKERS & PRI				
	BIOMARKERS & PRECISION MEDICINE SPATIA		PRECISION MEDICINE	DIGITAL PATHOLOGY & AI
CONFERENCE ROOM 1: TECHNOLOGIES FOR BIOMARKER ANALYSIS	CONFERENCE ROOM 2: BIOMARKER & MULTI-OMIC APPROACHES IN DISCOVERY & CLINICAL DEVELOPMENT FOR PERSONALIZED TREATMENT	CONFERENCE ROOM 3: APPLICATIONS OF SPATIAL RESEARCH & TECHNOLOGIES IN BIOLOGY	CONFERENCE ROOM 4: IMAGE ANALYSIS, AI-POWERED IMAGING FOR DIGITAL PATHOLOGY & SPATIAL BIOLOGY	CONFERENCE ROOM 5: UTILIZING DIGITAL PATHOLOGY IN PHARMA: DRUG DEVELOPMENT, CLINICAL TRIALS & PERSONALIZED MEDICINE
Beyond Blood - Leveraging Mass Spectrometry For Biomarker Identification In Unusual Matrices	Biomarker Discovery And Development For KRAS Inhibitors	TAMs in NSCLC: A Spatial & Single-Cell Dissection Of Their Role In Tumor Immunity		Spatial Multimodal Analysis For Histologic Characterization Of The Tumor Microenvironment
Mass spectrometry (MS)-based proteomics is essential in biomarker discovery, yet many projects focus solely on blood. In my talk, I will present our efforts to look for biomarkers beyond blood, highlighting how advancements	Successes of KRASG12C-targeting inhibitors sotorasib and adagrasib generated tremendous excitement although they only benefit a portion of all KRAS mutant cancer patients and resistance to treatment.	Phagocytosis is a fundamental function of macrophages, shaping both inflammatory and tissuerepair responses across disease contexts. However, the mechanisms regulating this process in human tumor-associated macrophages (TAMs) remain poorly defined. Here, we applied single-cell and spatial transcriptomics together with in		This talk presents preliminary work integrating H&E histology, spatial transcriptomics, and complementary assays using Al-driven spatial multiomics. We show how ST-informed
in MS sensitivity and throughput enable us to probe limited samples like tears and tape strips, broadening the horizons of biomarker discovery.	<ul> <li>invariably develops.</li> <li>Arduous work is ongoing in identifying pan-KRAS inhibitors which could benefit more patients and rationally designing combination strategies to overcome resistance.</li> <li>Biomarkers, especially ctDNA, play a key role in informing all these critical KRAS drug development activities. This presentation will summarize key recent findings and point out future directions in the KRAS-related biomarker space with a goal of achieving more advanced precision medicine.</li> </ul>	vitro coculture assays, to investigate Cancer cell Phagocytic TAMs (CP TAMs) in non-small cell lung cancer (NSCLC). We identified a novel CP TAM state marked by metabolic activity and antigen-presenting signatures and mapped the co-localized cell types influencing their functional status. Using single-cell spatial transcriptomics in independent NSCLC cohort confirmed these findings at single-cell resolution and revealed that CP TAMs modulate T effector cell activation. These insights provide a framework for therapeutic strategies aimed at reprogramming macrophage behavior to enhance anti-tumor immunity.	Attendees Are Welcome To Attend Co-Located Sessions	H&E phenotyping reveals gene expression signatures and potential prognostic markers. By combining spatial modalities, we uncover interactions within the tumor microenvironment (TME). Key challenges and future directions in data quality, interpretability, and clinical translation are discussed.
Jan Schejbal, Senior Scientist I – Proteomics, QTAS – Quantitative, Translational and ADME Sciences, <b>AbbVie</b>	I-MING WANG, Director, Translational Oncology, <b>Pfizer</b>	SERGEY NOVITSKIY, Principal Scientist, Amgen		JOSHUA J. LEVY, Director of Digital Pathology Research Assistant Professor of Pathology and Computational Biomedicine, <b>Cedars Sinai Medical</b> <b>Center</b>
		$\label{eq:Q&A} \textit{Q\&A session \& transition time between conference rooms}$		
Complement Proteins: Potential Biomarkers For Islet Autoimmunity And Type 1 Diabetes Onset	Using Early Somatic Variants To Predict Risk Of Late Stage Psychiatric Disorders	Spatial Proteomic Approach For Exploratory Neurobiology: Assessing The Biodistribution Of Viral Gene Therapy After CNS Delivery		Model Detection of the Seen and Unseen: A Multi-paradigm Approach to Histologic Anomaly Detection
Type 1 diabetes (T1D) results from autoimmune		Spatial proteomic approach for exploratory	Attendees Are Welcome To Attend Co-Located Sessions	Identifying rare abnormalities in toxicologic
β-cell destruction. We found that reduced complement protein levels precede the appearance of islet autoantibodies and persist through T1D onset. Children progressing to T1D show lower complement proteins than non-progressors, highlighting the complement pathway as a promising biomarker and therapeutic target for early prediction and prevention.		<ul> <li>neurobiology</li> <li>Overview of cyclic immunofluorescent platform</li> <li>Optimized neural panel for FFPE mouse brain</li> <li>Example 1: Cell phenotyping to define cell-type distribution of tool reporter AAV (FLAG-tagged)</li> <li>Example 2: Regional quantification of neuronal activation following chemically-induced seizure</li> <li>Example 3: Using spatial proteomics to "decode" capsid pools</li> </ul>		pathology is challenging. We introduce a framework that integrates supervised and unsupervised machine learning to characterize abnormalities in whole slide images. This approach, designed for existing pathologist workflows, demonstrates that deep learning-based anomaly detection is a promising tool for real-world applications in toxicological pathology.
BOBBIE-JO WEBB-ROBERTSON, Division Director, Chief Scientist, <b>Pacific</b> <b>Northwest National Laboratory</b>	GERALD QUON, Associate Professor, Department of Molecular and Cellular Biology, <b>University of California, Davis</b>	DANIELLE TAN, Senior Scientist I, <b>BioMarin</b>		FANGYAO HU, Senior Principal Scientist Al, Safety Assessment, <b>Genentech</b>
	Beyond Blood - Leveraging Mass Spectrometry For Biomarker Identification In Unusual Matrices  Mass spectrometry (MS)-based proteomics is essential in biomarker discovery, yet many projects focus solely on blood. In my talk, I will present our efforts to look for biomarkers beyond blood, highlighting how advancements in MS sensitivity and throughput enable us to probe limited samples like tears and tape strips, broadening the horizons of biomarker discovery.  Jan Schejbal, Senior Scientist I – Proteomics, QTAS – Quantitative, Translational and ADME Sciences, Abbvie  Complement Proteins: Potential Biomarkers For Islet Autoimmunity And Type 1 Diabetes Onset  Type 1 diabetes (T1D) results from autoimmune β-cell destruction. We found that reduced complement protein levels precede the appearance of islet autoantibodies and persist through T1D onset. Children progressing to T1D show lower complement proteins than non-progressors, highlighting the complement pathway as a promising biomarker and therapeutic target for early prediction and prevention.  BOBBIE-JO WEBB-ROBERTSON, Division Director, Chief Scientist, Pacific	CONFERENCE ROOM 1: TECHNOLOGIES FOR BIOMARKER ANALYSIS  Beyond Blood - Leveraging Mass Spectrometry For Biomarker Identification in Unusual Matrices  Mass spectrometry (MS)-based proteomics is essential in biomarker discovery, yet many projects focus solely on blood. In my talk, to seven a spectrometry (MS)-based proteomics is essential in biomarker discovery, yet many projects focus solely on blood. In my talk, to seven of blood, highlighting how advancements in MS sensitivity and throughput enable us to probe limited samples like tears and tage strips, broadening the horizons of biomarker discovery.  - Arduous work is ongoing in identifying pan- RRAS inhibitors with could benefit more patients and rationally designing combination strategles to overcome resistance.  - Biomarkers, especially ctDNA, play a key role in informing all these critical RRAS drug development activities. This presentation will summarize key recent findings and point out future directions in the RRAS-related biomarkers space with a goal of achieving more advanced precision medicine.  Jan Schejbal, Senior Scientist I - Proteomics, QTAS - Quantitative, Translational and ADME Sciences, Abbvie  Complement Proteins: Potential Biomarkers For Islet Autoimmunity And Type 1 Diabetes Onset  Using Early Somatic Variants To Predict Risk Of Late Stage Psychiatric Disorders  GERALD QUON, Associate Professor, Department of Molecular and Cellular Biology, University of California, Davis	CONFERENCE ROOM 1: TECHNOLOGIS FOR BIOMARKER ANALYSIS  Beyond Blood - Leveraging Mass Spectrometry For Biomarker cidentification in Unusual Matrices  Biomarker Discovery And Development For KRAS Inhibitors  Consideration in Unusual Matrices  Biomarker Discovery And Development For KRAS Inhibitors  Consideration in Unusual Matrices  Biomarker Discovery And Development For KRAS Inhibitors  Consideration in Unusual Matrices  Biomarker Discovery And Development For KRAS Inhibitors  Consideration in Unusual Matrices  Consideration in Unusua	DORFERENCE ROOM 1: TECHNOLOGIES FOR BIOMARKER ANALYSIS.  Beyond Blood - Leveraging Mass spectrometry for Giomarker International international processing in biomarker International int

Welcome

Highlights

Special Event Features

Sponsors

Agenda At A Glance

Speakers

FULL PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information



**VENUE INFORMATION** 

# The Westin St. Francis San Francisco on Union Square

The Westin St. Francis has been offering guests a warm welcome and an enriching, restorative stay since its opening in 1904. With its turn-of-the-20thcentury European style, this hotel in San Francisco's downtown area, blends the elegance of oak-paneled restaurants and the stately grandeur of the lobby with a \$45 million reinvention of the Landmark Building guest suites, ushering in a new chapter for this storied destination.

As the only hotel on Union Square, SF, it is close to the Financial District and Moscone Convention Center, and with cable cars just outside the front doors, they are at



335 Powell St, San Francisco, CA 94102, United **States** 

Venue Website





Highlights

Special Event **Features** 

**Sponsors** 

Agenda At A Glance

Speakers

PROGRAMME:

Day One 27 Oct, 2025

Day Two 28 Oct, 2025

Venue Information





